Early proof-of-concept study showed that a patch pump with integrated glucose sensing at the site of insulin delivery can ...

Dexcom G7 CGMs contain a complex electronic assembly within a wearable package that stands up to the rigors of everyday ...

Please provide your email address to receive an email when new articles are posted on . Mean sensor glucose and time in range improved slightly with a 1-year implantable CGM sensor compared with a 180 ...

With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption “Managing diabetes can be stressful and it is important for ...

This morning Belgian startup Indigo Diabetes announced a €38 million ($44.6 million) Series B funding round. This round included contributions from new investors Fund+, Ackermans&van Haaren, Capricorn ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship G7 sensor. The new system, which boosts wear time up from the previous ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

Continuous glucose monitoring in the GRADE trial shows that incretin-based drugs such as sitagliptin and liraglutide produce the most stable glycemic profiles and show the lowest hypoglycemia risk.

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...